Endometriosis targeted MRI imaging using bevacizumab-modified nanoparticles aiming at vascular endothelial growth factor

Qi Zhang, Caixia Fu, Qing Li, Yajie Li
In: ISMRM Annual Meeting · 2024 · doi:10.58530/2023/0436 · W4401573792
article OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-27 ⓘ

Bevacizumab-modified nanoparticles generated strong MRI signal enhancement in endometriosis lesions in rats, enabling targeted imaging.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-07, 2026-07-05 · read from full text ⓘ

This study examined endometriosis-targeted molecular MRI using bevacizumab-modified nanoparticles designed to target vascular endothelial growth factor. The authors generated nanoparticle-bound conjugates (NPBCNs) and evaluated their in vivo performance by measuring T1-weighted signal enhancement in endometriosis lesions in a rat model. They report strong MRI signal enhancement attributable to the nanoparticle targeting strategy. The paper’s explicitly stated caveat is that the accessible content is limited to an abstract-level meeting synopsis, rather than full experimental methodological and quantitative details. This paper is centrally about endometriosis — specifically targeted MRI imaging of endometriosis lesions using bevacizumab-modified VEGF-targeting nanoparticles.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

In vivo, NPBCNs generated strong signal enhancement in endometriosis lesion in rat on T1-weighted images via MRI.
Full text 1,366 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

#0436 DOI: https://doi.org/10.58530/2023/0436 Endometriosis targeted MRI imaging using bevacizumab-modified nanoparticles aiming at vascular endothelial growth factor Qi Zhang1, Caixia Fu2, Qing Li3, and Yajie Li4 1Department of Radiology, Huashan hospital, Fudan University, Shanghai, China, 2MR Application Development, Siemens Shenzhen Magnetic Resonance Ltd., Shenzhen, China, 3MR Collaborations, Siemens Healthineers Digital Technology (Shanghai) Co., Ltd., Shanghai, China, 4Fudan University, Shanghai, China Synopsis

Keywords

Uterus, Molecular ImagingIn vivo, NPBCNs generated strong signal enhancement in endometriosis lesion in rat on T1-weighted images via MRI. How to access this content: For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library. After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library. After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers. Click here for more information on becoming a member.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK